SEC Form 4	
------------	--

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	umber: 3235-0287				
Estimated average burden					
hours per response:	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] EHRLICH JASON		n*	2. Issuer Name and Ticker or Trading Symbol Kodiak Sciences Inc. [KOD]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
					Director	10% Owner	
				x	Officer (give title	Other (specify	
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)		below)	below)	
	()	(Middle)	07/20/2020		۲S		
2631 HANOVE	R STREET						
			A If Amendment Date of Original Filed (Menth/Dau/Maar)	C. In dia	idual as laint/Oraun Filing	(Chaoli Applicable	
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	Line)	idual or Joint/Group Filing	(Спеск Аррісаріе	
PALO ALTO	CA	94304		X	Form filed by One Repo	rting Person	
					Form filed by More than	One Reporting	
(City)	(State)	(Zip)			Person		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(a)		(1150.4)
Common Stock	07/20/2020		М		6,950	A	\$10.29	40,934	D	
Common Stock	07/20/2020		S ⁽¹⁾		1,474	D	\$49.767(2)	39,460	D	
Common Stock	07/20/2020		S ⁽¹⁾		5,100	D	\$50.573 ⁽³⁾	34,360	D	
Common Stock	07/20/2020		S ⁽¹⁾		376	D	\$51.19 ⁽⁴⁾	33,984	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

3. Transaction Date (Month/Day/Year) 1. Title of Derivative 3A. Deemed Execution Date 6. Date Exercisable and Expiration Date 7. Title and Amount of 8. Price of Derivative 9. Number of derivative 11. Nature of Indirect 5. Number 10. Ownership Conversion Transaction Code (Instr. of Derivative (Month/Day/Year) Security or Exercise if anv Securities Security Securities Form: Beneficial Price of Derivative Underlying Derivative Security Ownership (Instr. 4) (Instr. 3) (Month/Day/Year) 8) Securities (Instr. 5) Beneficially Direct (D) Acquired (A) or or Indirect (I) (Instr. 4) Owned (Instr. 3 and 4) Security Following Disposed of (D) (Instr. 3, 4 Reported Transaction(s) (Instr. 4) and 5) Amount ٥r Number Date Expiration of (D)Exercisable Title Shares Code v (A) Date Stock Option Commoi \$10.29 07/20/2020 Μ 6,950 (5) 08/29/2028 6,950 \$0.00 386,475 D (Right to Stock Buy)

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.

2. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from \$49.01 to \$49.95, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in these footnotes.

3. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from \$50.16 to \$50.90, inclusive.

4. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from \$51.18 to \$51.21, inclusive.

5. Twenty-five percent of the shares subject to the option vested on September 1, 2019 and 1/48th of the shares subject to the option vest on the same day of each month thereafter.

Remarks:

Chief Medical Officer and Chief Development Officer

/s/ Carlton Fleming, Attorney-
in-Fact for Jason Ehrlich

07/22/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.